{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/pruritus-ani/prescribing-information/chlorphenamine/","result":{"pageContext":{"chapter":{"id":"37717bd2-4921-5290-a6b8-f0a65ad0f747","slug":"chlorphenamine","fullItemName":"Chlorphenamine","depth":2,"htmlHeader":"<!-- begin field d47dec82-5f59-4b17-87d8-1b98e994dc3a --><h2>Chlorphenamine</h2><!-- end field d47dec82-5f59-4b17-87d8-1b98e994dc3a -->","summary":"","htmlStringContent":"<!-- begin item 317e3b08-8ceb-4e73-99a4-1e32a9d89d46 --><!-- end item 317e3b08-8ceb-4e73-99a4-1e32a9d89d46 -->","topic":{"id":"87896ca6-9aaa-5f82-80d8-9af6e6a4a7a9","topicId":"86164793-614e-4454-88db-d9e55aaa253a","topicName":"Pruritus ani","slug":"pruritus-ani","lastRevised":"Last revised in July 2016","chapters":[{"id":"f9039630-6980-5e4d-8b53-5f4a9a150404","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"b6f70111-057f-5e18-8eca-73d22e7a37fc","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"8b745278-e643-5f46-874e-0e59cc2271b0","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"2c6c2bd2-2780-5cda-90cd-0f0f1b291a90","slug":"changes","fullItemName":"Changes"},{"id":"57503895-5e7b-5b94-92cd-1d1516ca3df8","slug":"update","fullItemName":"Update"}]},{"id":"a3d4f578-5b09-55d8-b87e-5f3b001dacc0","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"ac52f024-a697-5997-b42a-163c6af60168","slug":"goals","fullItemName":"Goals"},{"id":"5f9315d6-bd64-5333-8d5c-94650869661f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"3819cff6-e1c5-5c6b-bd42-a3230e0dee66","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e5f4211b-d307-5395-8284-4852182fe149","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7288ccfe-7870-538b-b8ea-c991d02b41a4","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"4d207031-7d03-5c1c-862d-e2bc91d5f92b","slug":"nice-quality-standards","fullItemName":"NICE Quality standards"}]},{"id":"bd580148-0cf8-5dfd-ad32-519d9ac91ac6","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"d3973039-47c7-5366-9ce0-805dad2adffa","slug":"definition","fullItemName":"Definition"},{"id":"d40db160-dd24-516c-830c-f5d2ea3e292f","slug":"causes","fullItemName":"Causes"},{"id":"563df3bd-d0d2-5da3-b9d8-b9926d46f9d3","slug":"prognosis","fullItemName":"Prognosis"},{"id":"3190f567-6879-5e17-afa2-938933b25cdf","slug":"prevalence","fullItemName":"Prevalence"},{"id":"4dc56a97-ed78-5d3d-a7db-9fb8e99b315e","slug":"complications","fullItemName":"Complications"}]},{"id":"9240f15c-a3da-584f-a0c8-c129c79e4e32","fullItemName":"Management","slug":"management","subChapters":[{"id":"8b65829f-1484-5434-8d10-e778dcf736be","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"168bc91f-4693-57bd-a8d8-f94f8de33fe3","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"09b13ce9-39e9-5967-be36-6d6ad4971b30","slug":"topical-treatments","fullItemName":"Topical treatments"},{"id":"37717bd2-4921-5290-a6b8-f0a65ad0f747","slug":"chlorphenamine","fullItemName":"Chlorphenamine"}]},{"id":"81333760-2198-5943-b67a-82171b83e114","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"54290b12-c53b-5540-82ca-813deeebd19b","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"1fa3fbc1-b2c7-52ef-9dea-ae8969093694","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"c5b0b77c-5a39-5707-8719-949dd0d0c26e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"eac83458-255c-54b9-a370-647761527867","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"3b5e6536-aea6-5811-b6cc-15c63a12d8fe","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"1850e7a5-28b3-5f26-adc1-18d76f0d8848","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"85d0bc6e-70f1-5259-b3e0-164f534bd071","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"168bc91f-4693-57bd-a8d8-f94f8de33fe3","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"5ac5f948-61e1-5962-bab5-9087a341d81e","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field fdc45e11-14cb-4595-ac33-7eafb9ba2579 --><h3>What dose of chlorphenamine should I prescribe?</h3><!-- end field fdc45e11-14cb-4595-ac33-7eafb9ba2579 -->","summary":"","htmlStringContent":"<!-- begin item 732adefd-84c7-40cb-99e3-a5732b916eff --><!-- begin field 3af018c5-0bbb-44ed-a40e-37bfe995c736 --><ul><li><strong>The recommended oral doses of chlorphenamine </strong><strong>are:</strong><ul><li>Children aged 1 month–2 years: 1 mg twice daily.</li><li>Children aged 2–6 years: 1 mg every 4–6 hours (maximum of 6 mg daily).</li><li>Children aged 6–12 years: 2 mg every 4–6 hours (maximum of 12 mg daily).</li><li>Children aged over 12 years and adults: 4 mg every 4–6 hours (maximum 24 mg daily [12 mg in elderly people]).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pruritus-ani/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pruritus-ani/references/\">BNF 71, 2016</a>]</p><!-- end field 3af018c5-0bbb-44ed-a40e-37bfe995c736 --><!-- end item 732adefd-84c7-40cb-99e3-a5732b916eff -->","subChapters":[]},{"id":"f4112700-55a3-5fb0-8d4f-1c7c126a0df5","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 1f7d54a6-30b1-43af-82e6-79ecc6025738 --><h3>What are the adverse effects of chlorphenamine?</h3><!-- end field 1f7d54a6-30b1-43af-82e6-79ecc6025738 -->","summary":"","htmlStringContent":"<!-- begin item 756b8990-1bc8-4791-ac18-789ebd17e3b5 --><!-- begin field f54bc207-4947-43c2-96db-98ae8ced69a7 --><ul><li><strong>Adverse effects of chlorphenamine include:</strong><ul><li><strong>Neurological effects </strong>— dizziness, restlessness, psychomotor impairment, headaches, and sedation.<ul><li>Advise the person that sedation caused by chlorphenamine may affect their ability to drive or operate machinery. </li><li>These sedative effects are enhanced when chlorphenamine is combined with alcohol and may persist into the next day [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pruritus-ani/references/\">DTB, 2002</a>].</li></ul></li><li><strong>Anticholinergic effects </strong>— blurred vision, dry mouth, and urinary retention.</li><li><strong>Skin effects </strong>— urticaria, rash, exfoliative dermatitis, and photosensitivity.</li><li><strong>Gastrointestinal effects </strong>— nausea, vomiting, abdominal pain, diarrhoea, and dyspepsia.</li><li><strong>Cardiovascular effects </strong>— palpitations, tachycardia, and arrhythmias.</li><li><strong>Neuropsychiatric effects </strong>— depressed mood, excitation, irritability, nightmares, and confusion.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pruritus-ani/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pruritus-ani/references/\">BNF 71, 2016</a>]</p><!-- end field f54bc207-4947-43c2-96db-98ae8ced69a7 --><!-- end item 756b8990-1bc8-4791-ac18-789ebd17e3b5 -->","subChapters":[]},{"id":"3ff2770f-3c3e-5aff-9050-b15796cc2b7d","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 3af68299-de52-432f-b3a8-1493ee0c4eb3 --><h3>What are the contraindications and cautions with chlorphenamine?</h3><!-- end field 3af68299-de52-432f-b3a8-1493ee0c4eb3 -->","summary":"","htmlStringContent":"<!-- begin item d3b0a81b-90ad-4740-826b-f24bb28f19d3 --><!-- begin field 448c5c04-b2c4-443d-a9e7-e262e77d0ecf --><ul><li><strong>Do not use </strong><strong>chlorphenamine in people:</strong><ul><li>With severe liver disease.</li><li>Taking <a class=\"topic-reference internal-reference\" href=\"/topics/pruritus-ani/prescribing-information/chlorphenamine/#drug-interactions\">certain drugs</a>.</li></ul></li><li><strong>Use chlorphenamine with caution in:</strong><ul><li>People with:<ul><li>Mild to moderate hepatic impairment.</li><li>Renal impairment.</li><li>Benign prostatic hypertrophy.</li><li>Urinary retention.</li><li>Susceptibility to angle-closure glaucoma.</li><li>Severe hypertension or cardiovascular disease.</li><li>Raised intraocular pressure or glaucoma.</li><li>Pyloroduodenal obstruction.</li><li>Epilepsy (may reduce seizure threshold).</li><li>Asthma, bronchitis, or bronchiectasis.</li></ul></li><li>Children and elderly people (as they are more susceptible to adverse effects). </li><li>Pregnant or breastfeeding women:<ul><li><div>The manufacturer of chlorphenamine advises avoiding its use during pregnancy. However, the UK </div><div>Teratology Information Service (UKTIS) <em>bumps</em> patient information leaflets on chlorphenamine states that there is currently no evidence that chlorphenamine is harmful to a fetus. However, because only a small number of pregnant women have been studied, it is not possible to say for certain that it is completely safe. When deciding whether or not to use chlorphenamine during pregnancy, the benefits of treatment should be weighed against the possible risks [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pruritus-ani/references/\">BUMPS, 2014</a>].</div></li><li><div><div>The manufacturer of chlorphenamine advises avoiding its use during breastfeeding. However, </div><div>LactMed (a US drugs and lactation database) states that small (2 to 4 mg), occasional doses of chlorpheniramine are acceptable during breastfeeding, but larger doses or more prolonged use might cause effects in the infant or decrease the milk supply. Single bedtime doses after the last feeding of the day may be adequate for many women and will minimize any effects of the drug [<a class=\"bibliography-reference internal-reference\" href=\"/topics/pruritus-ani/references/\">LactMed, 2015</a>].</div></div></li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pruritus-ani/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pruritus-ani/references/\">BNF 71, 2016</a>]</p><!-- end field 448c5c04-b2c4-443d-a9e7-e262e77d0ecf --><!-- end item d3b0a81b-90ad-4740-826b-f24bb28f19d3 -->","subChapters":[]},{"id":"cdea34fd-94dc-5d54-9a4a-a0040746611c","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 7cb3ddb3-e9e5-437e-83d6-938ba094069f --><h3>What are the drug interactions of chlorphenamine?</h3><!-- end field 7cb3ddb3-e9e5-437e-83d6-938ba094069f -->","summary":"","htmlStringContent":"<!-- begin item db06bac8-66f1-4220-b2b0-c60ccf54879f --><!-- begin field 8bffd12b-0700-4041-8108-a26048bca388 --><ul><li><strong>Possible drug interactions of chlorphenamine include:</strong><ul><li><strong>Monoamine oxidase inhibitors (MAOIs) </strong>— the anticholinergic effects of chlorphenamine are intensified by MAOIs.<ul><li>Avoid chlorphenamine if the person has had an MAOI within the last 2 weeks.</li></ul></li><li><strong>Phenytoin</strong> — chlorphenamine inhibits phenytoin metabolism and can lead to phenytoin toxicity.<ul><li>If symptoms of toxicity (such as confusion, blurred vision, nystagmus, ataxia, or drowsiness) are present, monitor serum phenytoin levels and reduce the dose if necessary.</li></ul></li><li><strong>Antimuscarinic drugs</strong> — there is an increased risk of antimuscarinic adverse effects (such as dry mouth, urine retention, and constipation) when antihistamines are given with antimuscarinics. Concurrent use can also lead to confusion in elderly people.</li></ul></li><li><strong>In addition, the sedative effects of chlorphenamine may be increased by the following:</strong><ul><li>Alcohol.</li><li>Tricyclic (and tricyclic-related) antidepressants.</li><li>Hypnotic and anxiolytic drugs.</li><li>Opioid analgesics.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pruritus-ani/references/\">ABPI, 2016a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pruritus-ani/references/\">BNF 71, 2016</a>]</p><!-- end field 8bffd12b-0700-4041-8108-a26048bca388 --><!-- end item db06bac8-66f1-4220-b2b0-c60ccf54879f -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}